insulin NPH vs SAR341402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin NPH · Humulin N
Marketed by Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
Reported efficacy
Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)
Result source: NCT03211858
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin NPH | SAR341402 |
|---|---|---|
| HbA1c, change | —Not posted · NCT00604396 | -0.4% vs -0.3%vs NovoLog/NovoRapidNCT032118581 other result
|
| Body weight, change (kg) | 12.6 vs 13vs LevemirNCT01837680 | —Not reported |
| HbA1c below 7% | —Not posted · NCT00604396 | 19.6% vs 18.2%vs NovoLog/NovoRapidNCT032118581 other result
|
| Fasting plasma glucose, change | —Not posted · NCT00604396 | -0.1 vs -0.3vs NovoLog/NovoRapidNCT032118581 other result
|
| 3-point MACE (% with event) | —Not posted · NCT00604396 | —Not reported |
HbA1c, change
- insulin NPH
- —Not posted · NCT00604396
- SAR341402
- -0.4% vs -0.3%vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.3% vs -0.3% NCT03211858
Body weight, change (kg)
- insulin NPH
- 12.6 vs 13vs LevemirNCT01837680
- SAR341402
- —Not reported
HbA1c below 7%
- insulin NPH
- —Not posted · NCT00604396
- SAR341402
- 19.6% vs 18.2%vs NovoLog/NovoRapidNCT03211858
1 other result
- 16.6% vs 14.5% NCT03211858
Fasting plasma glucose, change
- insulin NPH
- —Not posted · NCT00604396
- SAR341402
- -0.1 vs -0.3vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.5 vs -0.2 NCT03211858
3-point MACE (% with event)
- insulin NPH
- —Not posted · NCT00604396
- SAR341402
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin NPH: 3 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin NPH | SAR341402 |
|---|---|---|
| Dropout rate | 19.2%a NCT01837680 · Phase na · registry result, not featured evidence | 12.3% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | —a NCT01837680 · Phase na · registry result, not featured evidence | 2.7% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Serious AEs | 0%a NCT01837680 · Phase na · registry result, not featured evidence | 12% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | a biochemical event of hypoglycemia 26.9% symptomatic hypoglycemia 21.2% rash 11.5% NCT01837680 · Phase na · registry result, not featured evidence | nasopharyngitis 11.3% upper respiratory tract infection 7.3% influenza 5% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin NPH
SAR341402
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin NPH's landscape · SAR341402's landscape